#Netherlands #Amsterdam #Berger Montague #uniQure #AMT-130

Important Deadline Approaches for uniQure N.V. Investors

In recent news from the world of biotechnology, a national law firm has announced the filing of a class action lawsuit against
uniQure N.V. (NASDAQ: QURE), an Amsterdam-based company focused on gene therapies. The lawsuit affects investors who acquired
the company's securities between September 24 and October 31, 2025. Investors are advised to be aware of the approaching deadline of
April 13, 2026, for seeking representation as lead plaintiffs in the case.

Background on uniQure N.V.

uniQure specializes in developing pioneering gene therapies targeting severe diseases, with Huntington's disease (HD) being one of its primary focus areas.
The company aims to revolutionize treatment options for such critical health conditions through innovative medical approaches.

Allegations of Misrepresentation

The complaint states that during the designated class period, uniQure allegedly misrepresented its progress and the regulatory
approval of its pivotal study concerning AMT-130, a treatment for Huntington's disease. Specifically, it is claimed that the firm did
not fully disclose key factors about the FDA's stance regarding the study design, including comparisons made with the ENROLL-HD external
historical data set. The absence of this information is believed to have misled investors, ultimately influencing their trading decisions.

Additionally, the lawsuit cites that uniQure downplayed the possibility of delays concerning its Biologics License Application (BLA)
timeline, which aims to secure market approval for AMT-130. Such assertions not only created a false sense of security among investors
but also potentially led to significant financial losses when the truth came to light.

Recent Developments

On November 3, 2025, uniQure faced a significant setback when it announced that the FDA did not consider its Phase I/II data adequate
for the BLA submission. This news shocked investors, culminating in a dramatic plummet of the company’s stock price. Following the
announcement, shares dropped from a closing price of $67.69 per share on October 31 to roughly $34.29 by the next trading day,
reflecting a drastic decline of over 49%.

This unforeseen downturn emphasizes the importance of the lawsuit's implications for affected investors. With the April 13, 2026, deadline on the horizon,
those who acquired shares during the specified period must act promptly to inquire about their legal options and potential claims.

How to Get Involved

Affected investors wishing to pursue this class action are encouraged to reach out to Berger Montague, the law firm leading
the charge for these claims. They can provide vital information on how individuals can assert their rights and what next steps
are warranted.

Contact information is available: Patients can reach Andrew Abramowitz at (215) 875-3015 or via email at [email protected],
or Caitlin Adorni at (267) 764-4865 or [email protected].

About Berger Montague

Berger Montague is well-regarded as a premier law firm in the United States, focusing on various areas of complex civil litigation,
inclusive of class actions. They have recovered substantial financial judgments for their clients over more than five decades of operation.

This situation surrounding uniQure N.V. serves as a critical reminder for investors in the biotechnology space to remain vigilant
and informed about the companies they are investing in. Understanding the implications of legal issues is vital to safeguarding
one's investments in a market that is often fraught with volatility and uncertainty.